Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study
Yao Huang, Zhe Chen, Yu Wang, Liang Han, Kai Qin, Wenya Huang, Ying Huang, Hui Wang, Pan Shen, Xin Ba, Weiji Lin, Hui Dong, Mingmin Zhang, Professor Shenghao Tu
Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217425
What is already known about this subject? ► On 12 March, WHO declared COVID-19 could be characterised as a pandemic. Till 22 April, more than 2.5 million cases of COVID-19 have been reported worldwide. ► Increasing data about COVID-19 based on the general population has been reported. However, little published works were found about COVID-19 in disease-specific groups. What does this study add? ► We analysed the epidemiology of 1255 inpatients with COVID-19 who were admitted to Wuhan Tongji Hospital. Additional 17 patients with systemic autoimmune diseases (AIDs) were further screened, the demographic characteristics, epidemiological history, comorbidities, clinical symptoms or signs on admission, chest CT findings, laboratory results on admission, therapies that were prescribed for COVID-19 as well as AIDs, and clinical outcomes were reported. The detailed information of patients with systemic AIDs was investigated.
Competing interests none declared. Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.
Patient consent for publication not required. Ethics approval This study was approved by the ethics Commission of Tongji Hospital, Tongji Medical College, Huazhong University of science and Technology (TJ-iRB20200365). Written informed consent was waived by Tongji Hospital for emerging infectious diseases and the urgent need to collect data. Provenance and peer review not commissioned; externally peer reviewed. data availability statement Data are available upon reasonable request by email to shtu@ tjh. tjmu. edu. cn. This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, on January 16, 2022 by guest. Protected by copyright. http://ard.bmj.com/
References
Chen N, Zhou, Dong, epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet,
doi:10.1016/S0140-6736(20)30211-7Clinicaltrials, Gov, Post-exposure prophylaxis / preemptive therapy for saRs-Coronavirus-2-full text view
Gautret, Parola, Hydroxychloroquine and azithromycin as a treatment of COViD-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105949Hari, Gs, Levy Ml, Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3), Nephron Clin Pract,
doi:10.1001/jama.2016.0289Hemminki, Huang, autoimmune diseases and hematological malignancies: exploring the underlying mechanisms from epidemiological evidence, Semin Cancer Biol,
doi:10.1016/j.semcancer.2019.06.005Kim Ahj, Sparks, Liew, a rush to judgment? rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COViD-19, Ann Intern Med,
doi:10.7326/M20-1223Li, Guan, Wu, early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N Engl J Med,
doi:10.1056/NEJMoa2001316Lu, Zhao, Li, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet,
doi:10.1016/S0140-6736(20)30251-8Smolen Js, Bijlsma, eUlaR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update, Ann Rheum Dis,
doi:10.1136/annrheumdis-2019-216655Subramanian Vs, Ga, Tumor necrosis factor alpha reduces intestinal vitamin C uptake: a role for nF-κB-mediated signaling, Am J Physiol Gastrointest Liver Physiol,
doi:10.1152/ajpgi.00071.2018Yao, Ye, Zhang, in vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (saRs-CoV-2), Clin Infect Dis,
doi:10.1093/cid/ciaa237Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COViD-19 in Wuhan, China: a retrospective cohort study, Lancet,
doi:10.1016/S0140-6736(20)30566-3
